5 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow TD-5108: new trials by email Literature Review of TD-5108 trials Research Report on TD-5108
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). Velusetrag 15 mg once daily for 4 weeks., Placebo once daily for 4 weeks. - Chronic Intestinal Pseudo-obstruction | Phase 2 | Completed | Alfasigma S.p.A. | 17 | 2021-12-15 | 2025-08-03 |
| The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study Velusetrag, Placebo - Gastroparesis | Phase 2 | Completed | Theravance Biopharma | 233 | 2014-12-01 | 2018-04-17 |
| Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis velusetrag dose 1, velusetrag dose 2, velusetrag dose 3 - Gastroparesis | Phase 2 | Completed | Theravance Biopharma | 34 | 2012-12-01 | 2018-02-26 |
| Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects Velusetrag, Placebo - Alzheimer's Disease | Phase 1 | Completed | Alfasigma S.p.A. | 40 | 2011-11-01 | 2025-07-08 |
| Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial) TD-5108 - Chronic Constipation | Phase 2 | Completed | Alfasigma S.p.A. | 360 | 2006-10-01 | 2025-07-08 |
Gastroparesis (2) · Alzheimer Disease (1) · Bronchiolitis Obliterans Syndrome (1) · Constipation (1)
Alfasigma S.p.A. (3) · Theravance Biopharma (2)
United States (3) · Belgium (1) · Italy (1) · Spain (1)